Remote monitoring between visits: fewer appointments, same finish?

An FDA-cleared remote-monitoring app analyzes patient-taken intraoral scans between visits. FDA granted it a new device classification in May 2024. Here is what the FDA decision summary supports.

Editorial · not sponsored L2 · Regulatory record

Evidence used: FDA De Novo decision summary
Checked: FDA De Novo decision summary. Oct 31, 2026 (ET)

Short answer · editorial read

Not shown by the sources in this draft. The FDA summary describes the app as an aid, not a stand-alone decision tool, and reports the sponsor's own detection figures. It does not measure visits, cost or outcomes.

Strongest source we used

1 Vendor claim
2 Regulatory record
3 Peer-reviewed study
4 Randomized trial

01 · Claims

What vendors and sponsors claim

Their own words or their own testing. Treated as claims until independently checked.

Sponsor: the app detects aligner seat/unseat problems. The detection figures in the FDA decision summary come from the sponsor's own clinical investigation program, as summarized for FDA (see checks and limits). Claim · sponsor data

We do not repeat vendor marketing. Vendor-website claims are not shown in this draft.

02 · What we checked

What we independently checked

What we could confirm from public records and peer-reviewed abstracts or full texts in this pass. Not a clinical study.

New FDA device type. De Novo DEN230035 was granted May 17, 2024, creating 21 CFR 872.1770, "dental image analyzer" (product code SBC, Class II). FDA defines it as a prescription home use device. Checked · De Novo summary
An aid, not a decision-maker. The decision summary says results are "an aid in diagnosis and monitoring, not on a stand-alone basis for clinical decision-making", for patients over 6, reporting on permanent teeth only. It lists no results on lingual surfaces or non-visible elements such as interproximal cavities. Checked · De Novo summary
Aligner tracking figures in the FDA summary. For seat/unseat tracking, the summary reports sensitivity of 93.2% (95% CI 91.3–94.7%) and specificity of 86.2% (83.4–88.6%) for detecting the condition, in a retrospective study read against a panel of independent orthodontists. Checked · De Novo summary

03 · Limits

Limits and what we could not verify

Gaps, caveats and anything we did not read.

Sponsor data in the FDA summary. The sensitivity and specificity figures come from the sponsor's clinical investigation program as summarized for FDA, not from an independent study. Limit · sponsor data
Detection is not fewer visits, lower cost or better outcomes. The source in this draft does not measure office visits, practice economics, chair time, missed problems or patient outcomes after retention. Gap · outcomes
No randomized trial found. We did not find a randomized comparison of remote monitoring against usual visits in this pass. Gap · level 4

Buyer takeaway: ask for the visit protocol used in any study you are shown, and track your own visits, emergency appointments and refinements for a defined period before and after adopting remote monitoring.

04 · Sources

Sources

De Novo decision summary DEN230035 (PDF) U.S. FDA · 2024 Partly read Indications, limitations, tracking results and benefit-risk sections read. Text extracted from a scanned PDF; some table labels were garbled.